Amylyx Pharmaceuticals
AMLX
27.43
-0.61
-2.18%
Amylyx Pharmaceuticals
US · AMLX
#2392 by market cap
Listed 2022
27.43
-0.61
-2.18%
Live - 5344 symbols - heartbeat 270s ago
· 2026-10-07 19:58
After-hours
27.43
0.00%
- Market cap
- 3.44B
- P/E (TTM)i
- -19.45
- P/Bi
- 14.39
- EPSi
- -1.53
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on AMLX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 71.83, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year -100.00% YoY
Margins
Key ratios & quality
- Altman Z-Scorei
- 71.83
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | 285.00K | 22.23M | 380.79M | 87.37M | 0 |
| Gross profit | -- | -- | 0 | 19.24M | 355.35M | -37.26M | 0 |
| Selling & admin expenses | 3.08M | 15.06M | 38.93M | 127.13M | 188.36M | 114.33M | 62.89M |
| Research & development | 11.90M | 24.59M | 44.04M | 93.45M | 128.19M | 104.08M | 90.40M |
| Operating profit | -13.55M | -39.01M | -82.69M | -201.34M | 38.80M | -255.68M | -153.29M |
| Pretax profit | -13.72M | -42.28M | -87.93M | -197.60M | 54.30M | -302.14M | -144.69M |
| Tax | -- | -- | 0 | 774.00K | 5.03M | -393.00K | 46.00K |
| Net profit | -13.72M | -42.28M | -87.93M | -198.38M | 49.27M | -301.74M | -144.74M |
| Basic EPS | 0 | -1 | -2 | -3 | 1 | -4 | -2 |
| Diluted EPS | -0.30 | -0.92 | -1.59 | -3.39 | 0.70 | -4.43 | -1.53 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | -- | 0 | 0 | 0 | -- |
| Gross profit | 0 | -- | 0 | 0 | 0 | -- |
| Selling & admin expenses | 15.68M | 15.64M | 16.17M | 15.39M | 16.17M | 21.93M |
| Research & development | 22.12M | 27.22M | 19.86M | 21.21M | 27.61M | 23.77M |
| Operating profit | -37.80M | -42.86M | -36.03M | -36.61M | -43.78M | -45.69M |
| Pretax profit | -35.91M | -41.44M | -34.39M | -32.95M | -41.28M | -43.42M |
| Tax | 0 | -- | 0 | 46.00K | -- | -- |
| Net profit | -35.91M | -41.44M | -34.39M | -33.00M | -41.28M | -43.42M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.42 | -0.46 | -0.37 | -0.30 | -0.37 | -0.39 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 3.20M | 13.64M | 104.95M | 382.13M | 464.67M | 189.43M | 323.67M |
| Cash & ST investments | 3.07M | 12.88M | 96.12M | 346.95M | 371.36M | 176.50M | 316.98M |
| Inventory | -- | -- | 0 | 9.77M | 38.32M | -- | -- |
| Total assets | 3.22M | 14.10M | 105.61M | 391.45M | 517.45M | 193.63M | 332.65M |
| Total current liabilities | 4.53M | 7.33M | 17.40M | 46.61M | 82.04M | 28.41M | 22.69M |
| Short-term debt | -- | -- | -- | 2.04M | 2.26M | 1.52M | 1.26M |
| Long-term debt | 14.93M | 1.43M | -- | -- | -- | -- | -- |
| Total liabilities | 28,577,000.00 | 80,829,000.00 | 256,782,000.00 | 50,846,000.00 | 84,022,000.00 | 28,869,000.00 | 27,386,000.00 |
| Total equity | -25.36M | -66.73M | -151.17M | 340.61M | 433.43M | 164.77M | 305.26M |
| Retained earnings | -25.63M | -67.91M | -155.85M | -354.22M | -304.95M | -606.69M | -751.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 216.14M | 186.89M | 353.38M | 323.67M | 285.02M | 256.34M |
| Cash & ST investments | 204.07M | 180.83M | 343.99M | 316.98M | 279.77M | 250.76M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 219.68M | 194.60M | 362.74M | 332.65M | 293.60M | 264.56M |
| Total current liabilities | 17.93M | 21.42M | 25.79M | 22.69M | 15.97M | 21.15M |
| Short-term debt | 1.06M | 665.00K | 981.00K | 1.26M | 1.16M | 1.01M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 18,259,000.00 | 26,721,000.00 | 30,745,000.00 | 27,386,000.00 | 20,442,000.00 | 25,397,000.00 |
| Total equity | 201.42M | 167.88M | 332.00M | 305.26M | 273.16M | 239.17M |
| Retained earnings | -642.60M | -684.04M | -718.43M | -751.43M | -792.71M | -836.13M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.69M | -36.70M | -74.80M | -179.87M | 11.92M | -167.65M | -123.34M |
| Depreciation & amortization | 0 | 1.00K | 52.00K | 487.00K | 1.09M | 904.00K | 525.00K |
| Free cash flow | -10.69M | -36.85M | -75.15M | -182.40M | 10.68M | -167.80M | -123.48M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 432.45M | -- | -- | -- |
| Ending cash balance | 3.09M | 13.07M | 50.38M | 63.25M | 170.92M | 78.84M | 227.64M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -39.82M | -25.25M | -30.37M | -27.90M | -36.88M | -31.42M |
| Depreciation & amortization | 156.00K | 141.00K | 120.00K | 108.00K | 98.00K | 43.00K |
| Free cash flow | -39.84M | -25.27M | -30.39M | -27.99M | -36.88M | -31.45M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 61.21M | 59.54M | 226.16M | 227.64M | 230.12M | 50.31M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -209.43 | 12.73 | -100.88 | -61.59 |
| ROA %i | -425.96 | -488.11 | -146.90 | -79.82 | 10.84 | -84.87 | -55.00 |
| ROIC %i | -- | -- | -- | -199.57 | 8.83 | -104.41 | -64.46 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -905.72 | 10.19 | -292.63 | -- |
| FCF / sales %i | -- | -- | -- | -- | 2.80 | -- | -- |
| Current ratioi | 0.71 | 1.86 | 6.03 | 8.20 | 5.66 | 6.67 | 14.27 |
| Quick ratioi | 0.68 | 1.76 | 5.53 | 7.77 | 5.01 | 6.23 | 13.98 |
| Debt / assetsi | 463.70 | 10.10 | 0.00 | 1.60 | 0.82 | 1.02 | 1.79 |
| LT debt / equityi | -- | -- | -- | 1.24 | 0.46 | 0.28 | 1.54 |
| Interest coveragei | -9.75 | -17.48 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -83.24 | -87.42 | -56.52 | -61.59 | -63.26 | -74.73 |
| ROA %i | -68.70 | -71.23 | -48.67 | -55.00 | -58.49 | -66.25 |
| ROIC %i | -86.84 | -89.97 | -58.72 | -64.46 | -66.34 | -77.51 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 13,470.91 | 64,567.07 | 23,660.15 | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 12.05 | 8.72 | 13.70 | 14.27 | 17.85 | 12.12 |
| Quick ratioi | 11.40 | 8.45 | 13.34 | 13.98 | 17.52 | 11.86 |
| Debt / assetsi | 0.63 | 3.06 | 1.64 | 1.79 | 1.92 | 1.99 |
| LT debt / equityi | 0.16 | 3.16 | 1.49 | 1.54 | 1.64 | 1.78 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenue, net100.00%
Region
United States100.00%
Quote time 2026-10-07 19:58:32 · For reference only, not investment advice and not tailored to your situation.